Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer.
about
A role for methyl-CpG binding domain protein 2 in the modulation of the estrogen response of pS2/TFF1 geneGeneration of a genomic tiling array of the human major histocompatibility complex (MHC) and its application for DNA methylation analysisThe histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cellsThe thymine DNA glycosylase MBD4 represses transcription and is associated with methylated p16(INK4a) and hMLH1 genesSpecific binding of the methyl binding domain protein 2 at the BRCA1-NBR2 locus.Bisphenol-A exposure in utero leads to epigenetic alterations in the developmental programming of uterine estrogen responseEpigenetic abnormalities in cardiac hypertrophy and heart failureSALL3 interacts with DNMT3A and shows the ability to inhibit CpG island methylation in hepatocellular carcinomaGenetic alteration and gene expression modulation during cancer progressionCombination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylationMeCP2: the chromatin connection and beyondUnique anti-glioblastoma activities of hypericin are at the crossroad of biochemical and epigenetic events and culminate in tumor cell differentiationMethylation detection oligonucleotide microarray analysis: a high-resolution method for detection of CpG island methylation.Next-generation technologies and data analytical approaches for epigenomics.Display of adenoregulin with a novel Pichia pastoris cell surface display system.SIGMA2: a system for the integrative genomic multi-dimensional analysis of cancer genomes, epigenomes, and transcriptomes.Methylation-sensitive enrichment of minor DNA alleles using a double-strand DNA-specific nuclease.Next-generation sequencing: from understanding biology to personalized medicine.A New Approach to Evaluating Aberrant DNA Methylation Profiles in Hepatocellular Carcinoma as Potential Biomarkers.Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications.Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosusThe transcriptional responsiveness of LKB1 to STAT-mediated signaling is differentially modulated by prolactin in human breast cancer cells.Epigenetics in metal carcinogenesis: nickel, arsenic, chromium and cadmium.Unique physical properties and interactions of the domains of methylated DNA binding protein 2.Methyl-CpG binding proteins: specialized transcriptional repressors or structural components of chromatin?Methods in DNA methylation profiling.Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylationEpigenetic mechanisms involved in the pathogenesis of hepatobiliary malignanciesChromatin remodeling in mammary gland differentiation and breast tumorigenesis.Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2.An evaluation of two-channel ChIP-on-chip and DNA methylation microarray normalization strategies.A DNA methylation fingerprint of 1628 human samples.NF-κB directly mediates epigenetic deregulation of common microRNAs in Epstein-Barr virus-mediated transformation of B-cells and in lymphomas.Expression of prolactin receptors in normal canine mammary tissue, canine mammary adenomas and mammary adenocarcinomas.CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer.Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.Expression profiling of DNA methylation-mediated epigenetic gene-silencing factors in breast cancer.Disrupted microRNA expression caused by Mecp2 loss in a mouse model of Rett syndromeEpigenetic gene silencing in cancer: the DNA hypermethylome.Epigenetic downregulation of atrial natriuretic peptide but not vasopressin mRNA expression in females with eating disorders is related to impulsivity.
P2860
Q21142628-46D3F803-9FB3-412D-A4AF-4C9175CE5824Q24288913-B300372D-61AE-4529-AA40-D814AE890F7FQ24336175-3D95F2FF-3534-422B-AA29-59CCCC1CE607Q24529077-EE487BE8-A0FE-441F-A87C-50A7C4B2CAEFQ24533103-6410CBD9-ED14-4360-AB51-9F472751567BQ24632509-7680F482-63E8-48E5-A2A3-D7B531C05855Q24644641-7DA7D597-67ED-4F46-8BEC-FECD1700B0B3Q24657710-F46857EA-B0CB-4812-832F-4F8D0C695110Q24798750-3D98D2F4-2FF3-481C-8DE8-1001239E6645Q25256831-52BE8557-4F5A-4D02-AF6A-E58836BA8A93Q28256925-A011FD85-174B-431A-9763-974CAD4A937DQ28533490-85EED60C-5F13-492F-8FB1-B71BDEC18E6CQ30488766-8817991B-0B45-47AF-BDC3-B419797B7657Q30712646-BB2C0ADF-E836-4C5F-87CF-083CA222428FQ33282135-87A4F65E-54AB-4A3F-B973-D318455260D3Q33374429-3E013E10-5D72-4464-BDEC-9768D5E932BFQ33557917-7B808845-2C81-4384-AE34-22CE9FFCBB98Q33565443-5938B8B8-4691-486F-A355-D9E5DD416A2EQ33572441-C8AE4CF9-DBA9-4623-9462-B42FAAE467F2Q33610854-5506DAD7-7728-43BE-AE58-B00DC1AADEE2Q33618909-4CA79664-2E09-4797-91DE-AEC61717A14BQ33783277-B416A287-268C-4182-9288-0016850FC67BQ33835721-13F01B4C-A012-4171-B109-D6644F39B271Q33860692-B6F48F7E-4D04-4857-9BB7-A1FE9A3BB621Q33864653-C0B644F5-47C2-40D9-B3C0-F422F9FECDFCQ33893167-C9DA33C5-DE9B-4006-AEA8-C92525B704E5Q33905462-96548B4F-E62E-423C-9E18-AA732B3C1CF4Q33907989-8B978C8A-D86D-4A7F-9C40-E76A6BC130D8Q34080232-87A6F6E2-E147-40D0-977B-62790F188FABQ34098728-85AF8950-9B69-4343-83AF-CDF40C3E38D3Q34140843-FA6E2971-35C3-4518-86C7-F43ADCF41067Q34187360-A667F392-0058-455A-B927-DE513E28F12EQ34248932-396BC8C0-536A-411F-8256-6E6E69DD272FQ34286753-95FF027A-EFB1-4273-8787-D1915A95A863Q34430590-CAA04ADB-E9B5-4E33-9B62-8E19741E1556Q34502198-3F146739-7BF2-450C-9161-C6527A6FB182Q34631368-D1684670-ED48-4AA2-9C15-2779A5BB9C23Q34643344-82930F9D-6E72-4A2A-B77D-4526F077564AQ34646556-EEFD03ED-9230-4FFE-AB3C-AB1AFDE8CFAFQ34732753-3C5320A9-2F56-4D93-A4D7-36DA2D387EC9
P2860
Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Methyl-CpG binding proteins id ...... inactivation in human cancer.
@ast
Methyl-CpG binding proteins id ...... inactivation in human cancer.
@en
Methyl-CpG binding proteins id ...... inactivation in human cancer.
@nl
type
label
Methyl-CpG binding proteins id ...... inactivation in human cancer.
@ast
Methyl-CpG binding proteins id ...... inactivation in human cancer.
@en
Methyl-CpG binding proteins id ...... inactivation in human cancer.
@nl
prefLabel
Methyl-CpG binding proteins id ...... inactivation in human cancer.
@ast
Methyl-CpG binding proteins id ...... inactivation in human cancer.
@en
Methyl-CpG binding proteins id ...... inactivation in human cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
Methyl-CpG binding proteins id ...... c inactivation in human cancer
@en
P2093
Juan Cruz Cigudosa
Maria F Paz
Mario F Fraga
Tim Hui-Ming Huang
P2860
P304
P356
10.1093/EMBOJ/CDG604
P407
P577
2003-12-01T00:00:00Z